Dr.Gregory K. Bell is quoted in this article published by BioPharm International about the regulatory and legal issues associated with bringing recent biosimilars and biobetters to market. Click below to read the article.
Potential impact of the CMS GENEROUS model
Reference country selection The model provided guidance on reference countries, defined by the G7 countries plus Denmark and Switzerland. Reference...
